YU28700A - Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije - Google Patents

Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije

Info

Publication number
YU28700A
YU28700A YU28700A YU28700A YU28700A YU 28700 A YU28700 A YU 28700A YU 28700 A YU28700 A YU 28700A YU 28700 A YU28700 A YU 28700A YU 28700 A YU28700 A YU 28700A
Authority
YU
Yugoslavia
Prior art keywords
hyperglycaemia
treatment
thiazolidinediones
mammal
pharmaceutically acceptable
Prior art date
Application number
YU28700A
Other languages
English (en)
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of YU28700A publication Critical patent/YU28700A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na upotrebu potencijatora osetljivosti na insulin za proizvodnju leka za lečenje hiperglikemije u kojoj su plazmatski nivoi glukoze u opsegu od >126 mg/dl do 140 mg/dl.[A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range of from > 126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitiser, to a mammal in need thereof.
YU28700A 1997-10-13 1998-10-12 Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije YU28700A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9721692.3A GB9721692D0 (en) 1997-10-13 1997-10-13 Novel treatment

Publications (1)

Publication Number Publication Date
YU28700A true YU28700A (sh) 2003-10-31

Family

ID=10820481

Family Applications (1)

Application Number Title Priority Date Filing Date
YU28700A YU28700A (sh) 1997-10-13 1998-10-12 Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije

Country Status (24)

Country Link
EP (1) EP1023057A1 (sh)
JP (1) JP2001519383A (sh)
KR (1) KR20010024482A (sh)
CN (1) CN1281358A (sh)
AP (1) AP1223A (sh)
AU (1) AU9547198A (sh)
BG (1) BG104405A (sh)
BR (1) BR9815220A (sh)
CA (1) CA2305289A1 (sh)
CZ (1) CZ20001298A3 (sh)
EA (1) EA200000418A1 (sh)
GB (1) GB9721692D0 (sh)
HR (1) HRP20000256A2 (sh)
HU (1) HUP0003673A3 (sh)
ID (1) ID24439A (sh)
IL (1) IL135515A0 (sh)
NO (1) NO20001897L (sh)
OA (1) OA11519A (sh)
PL (1) PL339804A1 (sh)
SK (1) SK5322000A3 (sh)
TR (1) TR200000957T2 (sh)
UA (1) UA66809C2 (sh)
WO (1) WO1999018944A1 (sh)
YU (1) YU28700A (sh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140664A0 (en) * 1998-07-21 2002-02-10 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus

Also Published As

Publication number Publication date
SK5322000A3 (en) 2000-09-12
CZ20001298A3 (cs) 2001-08-15
GB9721692D0 (en) 1997-12-10
UA66809C2 (uk) 2004-06-15
IL135515A0 (en) 2001-05-20
WO1999018944A1 (en) 1999-04-22
OA11519A (en) 2004-02-09
ID24439A (id) 2000-07-20
HUP0003673A3 (en) 2001-12-28
TR200000957T2 (tr) 2000-08-21
CN1281358A (zh) 2001-01-24
CA2305289A1 (en) 1999-04-22
AP2000001788A0 (en) 2000-06-30
BG104405A (en) 2000-12-29
KR20010024482A (ko) 2001-03-26
EP1023057A1 (en) 2000-08-02
NO20001897L (no) 2000-06-09
PL339804A1 (en) 2001-01-02
HRP20000256A2 (en) 2000-12-31
HUP0003673A2 (hu) 2001-10-28
NO20001897D0 (no) 2000-04-12
AP1223A (en) 2003-11-13
JP2001519383A (ja) 2001-10-23
EA200000418A1 (ru) 2000-10-30
BR9815220A (pt) 2000-11-14
AU9547198A (en) 1999-05-03

Similar Documents

Publication Publication Date Title
EP1787646A3 (en) Novel method of treatment
PL325825A1 (en) Microemulsion for use as a carrier for administering active compounds
MY124695A (en) Novel composition and use.
EP1127579A3 (en) Method for increasing bioavailability of oral pharmaceutical compositions
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
CA2040914A1 (en) Treatment of erectile dysfunction
WO2000016762A3 (en) Method for reducing nicotine dependency
AP2001002291A0 (en) Novel method of treatment.
WO2000007575A3 (en) Methods and compositions for increasing insulin sensitivity
MY106528A (en) Method of treating impotence.
WO1999004772A3 (en) Use of levobupivacaine
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
CA2350659A1 (en) Pharmaceutical composition for modified release insulin sensitiser
EP0744176A3 (en) Methods for inhibiting bone loss
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
BG101884A (en) Salts of the clavulanic acid
YU28700A (sh) Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
NZ503862A (en) Use of insulin sensitisers (especially thiazolidinediones) for the treatment of hyperglycaemia
AU2002236587A1 (en) Compositions for adhesion prevention
WO2000010590A3 (en) Cancer treatment